Irregular application of terbinafine or premature discontinuation of treatment leads to a relapse of the disease.
The duration of therapy can be influenced by factors such as the presence of concomitant diseases. The condition of the nails for the duration of therapy affects only with onychomycosis. If after 2 weeks of treatment there is noimprovement of the condition, it is necessary to repeatedly identify the causative agent of the disease and its sensitivity to the drug.
Systemic use in onychomycosis is justified only in case of total defeat of most nails, the presence of pronounced subungual hyperkeratosis, ineffectiveness of previous local therapy.
In the treatment of onychomycosis, a clinical response is usually observed a few months after mycological cure, confirmed laboratory and discontinuation of treatment, which is due to the rate of regrowth of a healthy nail. Removal of nail plates in the treatment of onychomycosis of the brushes for 3 weeks and onychomycosis of the feet for 6 weeks is not required.
When treating liver disease, terbinafine clearance can be reduced.
During treatment, it is necessary to monitor the activity of hepatic transaminases in the blood serum. In rare cases, after 3 months of treatment, there is cholestasis and hepatitis. If there is evidence of liver dysfunction (weakness, persistent nausea, loss of appetite, abdominal pain, jaundice, darkening of the urine or discolored stool), the drug should be discontinued.
The administration of terbinafine to psoriasis patients requires increased discretion;in very rare cases terbinafine can provoke an exacerbation of psoriasis.
When treating terbinafine, general hygiene rules should be followed to prevent the possibility of re-infection through linens and shoes. In the process of treatment (after 2 weeks), as well as in the end, it is necessary to produce antifungal treatment of shoes, socks and stockings.